

Tecentriq and Stability in Light

This letter responds to your request for information on Tecentriq® (atezolizumab) and stability in light.

In Brief

- Tecentriq vials for intravenous (IV) and subcutaneous (SC) administration should be protected from light and stored in the outer carton.
- Diluted IV solutions of Tecentriq in an infusion bag
 - should be protected from light, and are physically and chemically stable during a 30-day storage period in a fridge (2-8°C), and
 - are physically and chemically stable for 24 hours at 30°C, in ambient room light conditions.
- Prepared Tecentriq injections for SC administration
 - should be protected from light during a 30-day storage period in a fridge (2-8°C), and are physically and chemically stable for 8 hours at 30°C, in ambient room light conditions.

Recommendations for Tecentriq light storage conditions

Consult your local label for information on Tecentriq storage conditions. Table 1 describes the light storage conditions for Tecentriq IV and SC formulations.^{1,2}

Table 1. Light storage conditions for Tecentriq IV and SC formulations

Presentation	Storage temperature and duration	Storage condition
Vial of concentrate for infusion (IV formulation)	2°C to 8°C until date of expiry	Store in the outer carton to protect from light.
Diluted IV solution	2°C to 8°C for 30 days	Protect from light.
	≤30°C for 24 hours	Physically and chemically stable in ambient room light, including duration of administration.
Vial of solution for injection (SC formulation)	2°C to 8°C until date of expiry	Store in the outer carton to protect from light.

SC solution in syringe	2°C to 8°C for 30 days	Protect from light.
	≤30°C for 8 hours	Physically and chemically stable in ambient room light, including duration of administration.

References

1. Roche Internal Technical Report (Accessed on October 2024).
2. Roche Internal Regulatory Document (Accessed October 2024).